A major development in NSCLC: immunotherapy as first-line treatment
- Al B
- Oct 15, 2016
- 1 min read
The new data presented earlier this week showing that immunotherapy with pembrolizumab (Keytruda, Merck & Co) beats chemotherapy when used as first-line treatment of non-small cell lung cancer (NSCLC) electrified sessions here at the European Society for Medical Oncology (ESMO) Congress 2016.
Comments